Accepted for Publication: March 16, 2012.
Published Online: June 4, 2012. doi:10.1001/archneurol.2012.772. Corrected on July 20, 2012.
Author Contributions:Study concept and design: Savica and Boeve. Acquisition of data: Savica, Knopman, Jack, Lowe, and Boeve. Analysis and interpretation of data: Adeli, Vemuri, DeJesus-Hernandez, Rademakers, Fields, Whitwell, Lowe, Petersen, and Boeve. Drafting of the manuscript: Savica, Rademakers, and Lowe. Critical revision of the manuscript for important intellectual content: Savica, Adeli, Vemuri, Knopman, DeJesus-Hernandez, Fields, Whitwell, Jack, Lowe, Petersen, and Boeve. Statistical analysis: Savica, Vemuri, and Lowe. Obtained funding: Rademakers, Lowe, and Petersen. Administrative, technical, and material support: DeJesus-Hernandez, Jack, and Lowe. Study supervision: Rademakers, Lowe, Petersen, and Boeve.
Financial Disclosure: Dr Knopman serves as deputy editor for Neurology ; has served on a data safety monitoring board for Eli Lilly and Company; has served as a consultant for Elan/Janssen Alzheimer Immunotherapy; and is an investigator in clinical trials sponsored by Elan/Janssen Alzheimer Immunotherapy, Baxter International Inc, and Forest Laboratories Inc. Dr Knopman also receives research support from grants R01 AG011378 (coinvestigator), P50 AG016574 (coinvestigator), U01 AG006786 (coinvestigator), AG029550 (coinvestigator), AG032306 (coinvestigator), and U01 096917 (coinvestigator) from the National Institutes of Health. Ms DeJesus-Hernandezand Dr Rademakers have patent applications pending on the discovery of the C9ORF72 repeat expansion. Dr Rademakers also receives research support grants R01 NS065782 (principal investigator), R01AG026251 (coinvestigator), and P50 AG016574 (principal investigator, project 2) from the National Institutes of Health; as well as support from the ALS Association, the ALS Therapy Alliance, and the Consortium for Frontotemporal Degeneration Research. Dr Rademakers has also received honoraria for lectures or educational activities not funded by industry and serves on the medical advisory board of the Association for Frontotemporal Degeneration. Dr Jack serves on scientific advisory boards for Elan/Janssen Alzheimer Immunotherapy, Eli Lilly and Company, GE Healthcare, and Eisai Inc; and he receives research support from Baxter International Inc, Allon Therapeutics Inc, and Pfizer Inc. Dr Jack has also received grants R01 AG011378 (principal investigator) and P50 AG016574 (coinvestigator) from the National Institutes of Health/National Institute on Aging, as well as research support from the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. He also holds stock/stock options in Johnson and Johnson. Dr Lowe serves on scientific advisory boards for Bayer Schering Pharma and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, the National Institutes of Health (National Institute on Aging and National Cancer Institute), the MN Partnership for Biotechnology and Medical Genomics, and the Leukemia & Lymphoma Society. Dr Petersen serves on the safety monitoring committees for Elan Pharmaceuticals and Pfizer and as a consultant for Elan Pharmaceuticals and GE Healthcare. He also receives royalties from the publication of a book titled Mild Cognitive Impairment (Oxford University Press, 2003) and receives research support grants P50 AG016574 (principal investigator), U01 AG006786 (principal investigator), R01 AG011378 (coinvestigator), and U01 AG024904 (coinvestigator) from the National Institutes of Health. Dr Boeve serves as an investigator for clinical trials sponsored by Cephalon Inc, Allon Pharmaceuticals, and GE Healthcare and receives royalties from the publication of a book titled Behavioral Neurology of Dementia (Cambridge Medicine, 2009). He also receives research support grants P50 AG016574 (coinvestigator), U01 AG006786 (coinvestigator), and R01 AG032306 (coinvestigator) from the National Institutes of Health as well as research support from the Mangurian Foundation.
Funding/Support: This work was supported by the Mayo Alzheimer's Disease Research Center (P50 AG016574), the Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging (RO1 AG011378), the ALS Association (Dr Rademakers), and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation. Dr Rademakers' work is also funded by grants R01 NS065782 and R01 AG026251 from the National Institutes of Health.
Additional Contributions: We thank the patients and their families for participating in aging and neurodegenerative disease research. We appreciate the assistance of Samantha Wille, BS, in generating the magnetic resonance images.